Latest Breaking News On - தேர்ந்தெடுக்கப்பட்ட தடுப்பான் ஆஃப் அணு ஏற்றுமதி - Page 3 : vimarsana.com

TodayIR: Antengene Announces its U S Partner, Karyopharm Therapeutics Inc , has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

(2) DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO(R) Addressable Patient Population - Oral XPOVIO(R) is Now the Only Approved Multiple Myeloma Drug Indicated

United statesHong kongJay meiAsia pacificSelective inhibitor of nuclear exportKaryopharm therapeutics incDrug administrationAustralian therapeutic goods administrationHealth sciences authorityApproval programEuropean medicines agencyAntengene corporation limitedNational medical products administrationConnective tissue oncology societyNational comprehensive cancer networkAntengene announces

TodayIR: Antengene Announces its U S Partner, -2-

TodayIR: Antengene Announces its U S Partner, -2-
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesHong kongKostenloser wertpapierhandelJay meiAsia pacificSelective inhibitor of nuclear exportKaryopharm therapeutics incMarketing pressDrug administrationAntengene corporation limitedAustralian therapeutic goods administrationApproval programHealth sciences authorityEuropean medicines agencyConnective tissue oncology societyNational medical products administration

FDA Approves Selinexor Combination Treatment for Certain Patients With Multiple Myeloma

FDA Approves Selinexor Combination Treatment for Certain Patients With Multiple Myeloma
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.

United statesMichaelg kauffmanPaul richardsonSharon shachamSelective inhibitor of nuclear exportKaryopharm therapeutics incApproval programClinical researchClinical program leaderSelective inhibitorNuclear exportChief scientific officerIndependent review committeeJerome lipper multiple myeloma centerDana farber cancer instituteChief executive officer

Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
homenewshere.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from homenewshere.com Daily Mail and Mail on Sunday newspapers.

United statesMichaelg kauffmanPaul richardsonSharon shachamSelective inhibitor of nuclear exportKaryopharm therapeutics incNational cancer instituteDrug administrationTakeda pharmaceutical companyExchange commissionApproval programEuropean unionKaryopharm selective inhibitor of nuclear exportEuropean medicines agencyClinical researchInformation department

Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: Dec 15, 2020 NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel. Mr. Mano brings over 15 years of legal experience and previously served as Counsel, Business Development at Biogen Inc. Michael s depth of legal experience, particularly in the public life science sector supporting partnerships, intellectual property licensing, corporate governance, and financing efforts, will be valuable to Karyopharm as we continue to grow our commercial business and work to expand the reach of XPOVIO and our other pipeline assets worldwide, said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm.

United statesMichaelg kauffmanSelective inhibitor of nuclear exportKaryopharm therapeutics incDrug administrationBusiness development at biogen incPrnewswire karyopharm therapeutics incExchange commissionLouis school of lawSenior counsel at proskauer roseKaryopharm selective inhibitor of nuclear exportCompensation committee of karyopharm board directorsEuropean medicines agencySaint michael collegeWashington university in stMichael mano